相关实验视频

Updated: Jan 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

在临床前黑色素瘤模型中,由PROTAC介导的Bcl-xL降解增强了向治疗的潜能

Elisabetta Valentini¹, Giulia Gentile¹, Marta Di Martile¹

¹Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, Italy.

Journal of experimental & clinical cancer research : CR

|January 8, 2026

概括

DT2216,一种新的Bcl-xL降解剂,通过增强向疗法和减少瘤生长,在黑色素瘤治疗中表现有前途. 这种方法为针对黑色素瘤的组合策略提供了新的见解.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物开发药物开发

背景情况:

Bcl-xL是黑色素瘤的关键蛋白质,是BH3模仿剂的目标,具有不良影响.
选择性Bcl-xL蛋白质分解向的嵌合体降解剂,如DT2216,提供了一个替代方法.
在临床前的模型中,DT2216已经显示出抗瘤活性,但在黑色素瘤中还没有.

研究的目的:

评估DT2216在黑色素瘤细胞中的疗效.
研究DT2216在黑色素瘤组合疗法中的潜力.
评估DT2216对Bcl-xL降解和细胞活性的影响.

主要方法:

西部斑点和MTT试验被用来评估DT2216对Bcl-xL水平和细胞活性的影响.
进行了对DT2216和向疗法 (达布拉费尼布/特拉美替尼布) 或Mcl-1抑制剂 (S63845) 的组合研究.
在体内异种移植的小鼠模型被用于评估组合治疗的疗效.

主要成果:

DT2216诱导了特定的,持久的Bcl-xL降解和降低了黑色素瘤细胞活力.
DT2216增强了针对性疗法的疗效,不论BRAF突变状态如何.
DT2216在黑色素瘤异种移植模型中证明了向治疗的强化作用,减少了瘤生长并改善了疾病控制.

结论:

DT2216显示出作为黑色素瘤治疗剂的显著潜力.
涉及Bcl-xL降解的组合疗法代表了黑色素瘤治疗的有希望的策略.
对于黑色素瘤患者,对基于DT2216的组合疗法的进一步研究是有必要的.

关键词:

在 Bcl-xL 中.DT221616 这是一个很好的机会.黑色素瘤是一种黑色素瘤.这就是PROTAC.目标疗法目标疗法

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...